Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

Watch our Webinar on myeloma and infections

We held our latest webinar on September 11th, called Myeloma and infection: clinical and lived perspectives for myeloma patients, carers and advocates. Jackie Quinn, Myeloma Clinical Nurse Specialist, Belfast Trust presented on how myeloma and treatments increase infection risk, covering immunisations, bispecific antibody risks, and preventive medications. Mimi Quinn, myeloma patient from Ireland shared her personal…

Read more

Myeloma and infection: clinical and lived perspectives webinar

Myeloma Patients Europe (MPE) will host a webinar on “Myeloma and infection: clinical and lived perspectives” on Thursday, 11th September 2025 from 17:00 – 18:00 CEST. Aimed at myeloma patients, carers and patient advocates, the webinar will feature presentations on infection risk and prevention in myeloma, and a patient’s experiences of infection in myeloma. Jackie Quinn,…

Read more

The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patients

Two belantamab mafodotin (Blenrep®) combinations, with bortezomib and dexamethasone or pomalidomide and dexamethasone, are now authorised for use in the European Union. The decision follows an earlier positive recommendation of European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP – their scientific advisory committee) on 23 May 2025. Marketing authorisation means that…

Read more

New guidelines for the treatment and the management of myeloma and smouldering myeloma

On July 7th, 2025, new clinical management guidelines for myeloma and smouldering myeloma were published in Nature Reviews Clinical Oncology by myeloma experts. These guidelines are written to guide doctors and healthcare professionals in myeloma and smouldering myeloma diagnosis, treatment and follow-up, based on the most up-to-date scientific knowledge. The last treatment guidelines were published in…

Read more

EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myeloma

On the 19th June 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended  marketing authorisation for daratumumab for patients with high-risk smouldering myeloma. Daratumumab is a monoclonal antibody marketed by Johnson & Johnson as Darzalex®. This medicine has been designed to recognise and bind to the CD38 protein, which is found on the surface…

Read more
August

September 2026

October
MO
TU
WE
TH
FR
SA
SU
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
Events for 1st September
No Events
Events for 2nd September
No Events
Events for 3rd September
No Events
Events for 4th September
No Events
Events for 5th September
No Events
Events for 6th September
No Events
Events for 7th September
No Events
Events for 8th September
No Events
Events for 9th September
No Events
Events for 10th September
No Events
Events for 11th September
No Events
Events for 12th September
No Events
Events for 13th September
No Events
Events for 14th September
No Events
Events for 15th September
No Events
Events for 16th September
No Events
Events for 17th September
No Events
Events for 18th September
No Events
Events for 19th September
No Events
Events for 20th September
No Events
Events for 21st September
No Events
Events for 22nd September
No Events
Events for 23rd September
No Events
Events for 24th September
No Events
Events for 25th September
No Events
Events for 26th September
No Events
Events for 27th September
No Events
Events for 28th September
No Events
Events for 29th September
No Events
Events for 30th September
No Events